Literature DB >> 11083685

Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina.

C M Luna1, A Famiglietti, R Absi, A J Videla, F J Nogueira, A D Fuenzalida, R J Gené.   

Abstract

OBJECTIVE: To survey the etiology and epidemiology of community-acquired pneumonia (CAP) in relation to age, comorbidity, and severity and to investigate prognostic factors.
DESIGN: Prospective epidemiologic study, single center.
SETTING: University hospital at Buenos Aires, Argentina. PATIENTS: Outpatients and inpatients fulfilling clinical criteria of CAP.
INTERVENTIONS: Systematic laboratory evaluation for determining the etiology, and clinical evaluation stratifying patients into mild, moderate, and severe CAP (groups 1 to 3), a clinical rule used for hospitalization.
RESULTS: During a 12-month period, 343 patients (mean age, 64.4 years; range, 18 to 102 years) were evaluated. We found 167 microorganisms in 144 cases (yield, 42%). Streptococcus pneumoniae, the most common pathogen, was isolated in 35 cases (24%). Mycoplasma pneumoniae, present in 19 (13%), was second in frequency in group 1; Haemophilus influenzae, present in 17 cases (12%), was second in group 2; and Chlamydia pneumoniae, present in 12 cases (8%), was second in group 3. Etiology could not be determined on the basis of clinical presentation; identifying the etiology had no impact on mortality. Some findings were associated with specific causative organisms and outcome. A significantly lower number of nonsurvivors received adequate therapy (50% vs 77%).
CONCLUSIONS: Age, comorbidities, alcohol abuse, and smoking were related with distinct etiologies. PaO(2) to fraction of inspired oxygen ratio < 250, aerobic Gram-negative pathogen, chronic renal failure, Glasgow score < 15, malignant neoplasm, and aspirative pneumonia were associated with mortality by multivariate analysis. Local microbiologic data could be of help in tailoring therapeutic guidelines to the microbiologic reality at different settings. The stratification schema and the clinical rule used for hospitalization were useful.

Entities:  

Mesh:

Year:  2000        PMID: 11083685     DOI: 10.1378/chest.118.5.1344

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  44 in total

1.  Poor clinical outcomes among pneumonia patients with schizophrenia.

Authors:  Yi-Hua Chen; Hsiu-Chen Lin; Herng-Ching Lin
Journal:  Schizophr Bull       Date:  2010-03-25       Impact factor: 9.306

2.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

3.  Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil.

Authors:  Joao Tonolio Neto; Gabriela Tannus Branco de Araujo; Anna Gagliardi; Amanda Pinho; Laure Durand; Marcelo Fonseca
Journal:  Hum Vaccin       Date:  2011-10-01

Review 4.  Q fever in French Guiana.

Authors:  Carole Eldin; Aba Mahamat; Magalie Demar; Philippe Abboud; Félix Djossou; Didier Raoult
Journal:  Am J Trop Med Hyg       Date:  2014-08-04       Impact factor: 2.345

5.  Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery.

Authors:  K Krobot; D Yin; Q Zhang; S Sen; A Altendorf-Hofmann; J Scheele; W Sendt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-08-21       Impact factor: 3.267

6.  Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia.

Authors:  Samuel M Brown; Barbara E Jones; Al R Jephson; Nathan C Dean
Journal:  Crit Care Med       Date:  2009-12       Impact factor: 7.598

7.  [Update to the Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia].

Authors: 
Journal:  Arch Bronconeumol       Date:  2004-08       Impact factor: 4.872

Review 8.  Improving outcomes of elderly patients with community-acquired pneumonia.

Authors:  Félix Gutiérrez; Mar Masiá
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

9.  Development of real-time multiplex nucleic acid sequence-based amplification for detection of Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella spp. in respiratory specimens.

Authors:  K Loens; T Beck; D Ursi; M Overdijk; P Sillekens; H Goossens; M Ieven
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

Review 10.  International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.

Authors:  Thomas M File; James S Tan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.